ZA200304092B

ZA200304092B - Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use.

Info

Publication number: ZA200304092B
Application number: ZA200304092A
Authority: ZA
Inventors: Heiner Glombik; Werner Kramer; Stefanie Flohr; Wendelin Frick; Hubert Heuer; Gerhard Jaehne; Andreas Lindenschmidt; Hans-Ludwig Schaefer
Original assignee: Aventis Pharma Gmbh
Priority date: 2000-12-21
Filing date: 2003-05-27
Publication date: 2004-04-19
Also published as: RU2275370C2; RU2282628C2; DE10064402A1; ZA200304095B

Description

Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use

The invention relates to substituted diphenylazetidinones, to their physiologically acceptable salts and to derivatives having physiological function. Diphenylazetidinones (such as, for example, ezetimibe) and their use for treating hyperlipidemia and arteriosclerosis and hypercholesterolemia have already been described [cf. Drugs of the Future 2000, 25(7):679-685). :

It was an object of the invention to provide further compounds having a therapeutically utilizable hypolipidemic action. In particular, it was an object to find novel compounds which, compared to the compounds described in the prior art, are absorbed to a very low extent. Very low absorption is to be understood as meaning an intestinal absorption of less than 10%, preferably less than or equal to 5%.

In particular, absorption of the novel compounds must be less than that of ezetimibe.

Pharmaceutically active compounds which are absorbed to a very low extent generally have considerably fewer side-effects.

i. Accordingly, the invention relates to compounds of the formula |,

R1

OH

. «

OP R2

N

R5 (0 ry"

R4 in which

R1, R2, R3, R4, R5, R6 independently of one another are (Co-Cao)- alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)-, -CH=CH-, -C=C-, -N((C1-Cé)-alkyl)- or -NH-;

H, F, Cl, Br, |, CFs, NO2, CN, COOH, COO(C,-Cg)alkyl, CONH,

CONH(C4-Ce)alkyl, CON[(C+-Cg)alkyll,, (C1-Cé)-alkyl, (C2-Ce)-alkenyl, (C2-Ce)-alkynyl, O-(C4-Ce)-alkyl, where one or more hydrogens in the alkylene radicals may be replaced by fluorine;

SO2-NH2, SO,NH(C,-Ce)-alkyl, SOzN[(C1-Ce)-alkyl], , S-(C4-Ce)-alkyl, S- (CHz)n-phenyl, SO-(C4-Ce)-alkyl, SO-(CHa)n-phenyl, SO,-(C1-Ce)-alkyl,

SO2-(CHz)n-phenyl, where n = 0 — 6 and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CFs, NO,, CN, OCF,

O-(C1-Ce)-alkyl, (C4-Ce)-alkyl, NH;

NHz, NH-(C4-Ce)-alkyl, N((C1-Ce)-alkyl)z, NH(C1-C)-acyl, phenyl,

O-(CHgz)n-phenyl, where n = 0 — 6, where the phenyl ring may be mono- to trisubstituted by F, Cl, Br, |, OH, CF3, NO, CN, OCF3, O-(C1-Ce)- alkyl, (C1-Ce)-alkyl, NHz, NH(C4-Cg)-alkyl, N((C4-Ce)-alkyl)s, SO2-CHj,

COOH, COO-(C4-Cg)-alkyl, CONH;

L — 0) > 0)

R1 g ® i

On

R8

N (S

Formula l

L

R7 is methyl, ethyl, propyl, butyl;

R8 is H, OH, NH, NH-(C,-C¢)-alkyt;

R9 is methyl, ethyl, propyl, butyl;

R10 is methyl, ethyl, propyl, butyl; where in each case at least one of the radicals R1 to R6 must have the meaning (Co-Cao)-alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)-, -CH=CH-, -C=C-, -N((C1-Cs)-alkyl)- or -NH-, and its pharmaceutically acceptable salts.

Preference is given to compounds of the formula |, in which at least one of the radicals R1 to R6 has the meaning (Co-C3)-alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)- or -NH-.

Particular preference is given to compounds of the formula |, in which one of the radicals R1 or R3 has the meaning (Co-C3o)-alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)- or -NH-.

3 ® ) Very particular preference is given to compounds of the formula I, in which one of the radicals R1 or R3 has the meaning -(CHz)o.1-NH-(C=0) ¢-1-(C3-Cas)-alkylene- (C=0)o-1-NH-L, where one or more carbon atoms of the alkylene radical may be replaced by oxygen atoms.

One of the radicals R1 to R6 is preferably attached to the L radical in the meta position of ring C of the L group.

Owing to their increased solubility in water, compared to the parent compounds, pharmaceutically acceptable salts are particularly suitable for medical applications.

These salts must have a pharmaceutically acceptable anion or cation. Suitably pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid, and of organic acids, such as acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isothionic acid, lactic : acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p- toluenesulfonic acid, tartaric acid and trifluoroacetic acid, for example. For medical purposes, very particular preference is given to using the chloride salt. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium : and calcium salts).

The scope of the invention also includes salts having a pharmaceutically unacceptable anion, which salts may be useful intermediates for preparing or purifying pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.

Here, the term "derivative having physiological function" refers to any physiologically acceptable derivative of a compound according to the invention, for example an ester, capable of forming, upon administration to a mammal, for example man, such

. ® a compound or an active metabolite (directly or indirectly).

A further aspect of this invention are prodrugs of the compounds according to the invention. Such prodrugs can be metabolized in vivo to give a compound according to the invention. These prodrugs may or may not be active in their own right.

The compounds according to the invention can also be present in various polymorphic forms, for example as amorphous and crystalline polymorphous forms. :

The scope of the invention includes all polymorphic forms of the compounds according to the invention, which form a further aspect of the invention.

Hereinbelow, all references to “compound(s) of formula (l)* refer to a compound or ~ compounds of the formula (I) as described above, and to their salts, solvates and derivatives having physiological function, as described herein.

The compounds of the formula | and their pharmaceutically acceptable salts and derivatives having physiological function are ideal medicaments for treating an impaired lipid metabolism, in particular hyperlipidemia. The compounds of the formula | are also suitable for modulating the serum cholesterol concentration and for preventing and treating arteriosclerotic symptoms.

The compound(s) of the formula (I) can also be administered in combination with other active compounds.

The amount of a compound of the formula (1) required to achieve the desired biological effect depends on a number of factors, for example on the specific compound chosen, on the intended use, on the mode of administration and on the clinical condition of the patient. In general, the daily dose is in the range from 0.1 mg to 100 mg (typically from 0.1 mg to 50 mg) per day per kilogram of bodyweight, for example 0.1-10 mg/kg/day. Tablets or capsules may contain, for example, from 0.01 to 100 mg, typically from 0.02 to 50 mg. In the case of pharmaceutically acceptable salts, the abovementioned weight data relate to the weight of the dipheny!-

@ azetidinone-ion derived from the salt. For the prophylaxis or therapy of the ) abovementioned conditions, the compounds of the formula (I) can be used ~ themselves as the compound, but preferably they are present in the form of a pharmaceutical composition with an acceptable carrier. The carrier must of course be acceptable in the sense that it is compatible with the other constituents of the composition and is not harmful to the health of the patient. The carrier can be a solid or a liquid or both and is preferably formulated with the compound as an individual dose, for example as a tablet, which can contain from 0.05% to 95% by weight of the active compound. Further pharmaceutically active substances can also be present, including further compounds of the formula (1). The pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which essentially consists in mixing the constituents with pharmaceutically acceptable carriers and/or auxiliaries.

Pharmaceutical compositions according to the invention are those which are suitable for oral or peroral (e.g. sublingual) administration, although the most suitable manner of administration is dependent in each individual case on the nature and severity of - the condition to be treated and on the type of the compound of the formula (I) used in each case. Coated formulations and coated delayed-release formulations are also included in the scope of the invention. Acid-resistant and enteric formulations are preferred. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylicellulose phthalate and anionic polymers of methacrylic acid and methylmethacrylate.

Suitable pharmaceutical compounds for oral administration can be present in separate units, such as, for example, capsules, cachets, lozenges or tablets, which in each case contain a specific amount of the compound of the formula (1); asa powder or granules; as a solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions can be prepared according to any suitable pharmaceutical method which includes a step in which the active compound and the carrier (which can consist of one or more additional constituents) are brought into contact. In general,

: ® i the compositions are prepared by uniform and homogeneous mixing of the active ) compound with a liquid and/or finely divided solid carrier, after which the product, if necessary, is shaped. For example, a tablet can thus be prepared by pressing or shaping a powder or granules of the compound, if appropriate with one or more additional constituents. Pressed tablets can be produced by tableting the compound in free-flowing form, such as, for example, a powder or granules, if appropriate mixed with a binder, lubricant, inert diluent and/or a (number of) surface-active/ dispersing agent(s) in a suitable machine. Shaped tablets can be produced by shaping the pulverulent compound moistened with an inert liquid diluent in a suitable machine.

Pharmaceutical compositions which are suitable for peroral (sublingual) administration include lozenges which contain a compound of the formula (1) with a flavoring, customarily sucrose and gum arabic or tragacanth, and pastilles which include the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.

Suitable other active compounds for the combination preparations are: all antidiabetics, mentioned in Rote Liste 2001, Chapter 12. They can be combined with the compounds of the formula | according to the invention in particular to achieve a synergistically enhanced action. The active compound combination can be administered either by separate administration of the active compounds to the patient or in the form of combination preparations comprising a plurality of active compounds in a pharmaceutical preparation.

Antidiabetics include insulin and insulin derivatives, such as, for example, Lantus* or

HMR 1964, GLP-1 derivatives, such as, for example, those disclosed by Novo

Nordisk A/S in WO 98/08871, and oral hypoglycemic active compounds.

The oral hypoglycemic active compounds preferably include sulphonyl! ureas, biguadines, meglitinides, oxadiazolidindiones, thiazolidindiones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potassium channel openers, such

: ® ] as, for example, those disclosed by Novo Nordisk A/S in WO 97/26265 and

WO 99/03861, insulin sensitizers, inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, compounds which modulate lipid metabolism, such as antihyperlipidemic active compounds and antilipidemic active compounds, compounds which reduce food intake, PPAR and

PXR agonists and active compounds which act on the ATP-dependent potassium channel of the beta celis.

In one embodiment of the invention, the compounds of the formula | are administered in combination with a HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin.

In one embodiment of the invention, the compounds of the formula | are administered in combination with a cholesterol absorption inhibitor, such as, for example, ezetimibe, tiqgueside, pamaqueside.

In one embodiment of the invention, the compounds of the formula | are administered in combination with a PPAR gamma agonist, such as, for example, rosiglitazone, pioglitazone, JTT-501, Gl 262570. in one embodiment of the invention, the compounds of the formula | are administered in combination with a PPAR alpha agonist, such as, for example, GW 9578, GW 7647.

In one embodiment of the invention, the compounds of the formula | are administered in combination with a mixed PPAR alpha/gamma agonist, such as, for example, GW 1536, AVE 8042, AVE 8134, AVE 0847.

In one embodiment of the invention, the compounds of the formula | are administered in combination with a fibrate, such as, for example, fenofibrate, clofibrate, bezafibrate.

) In one embodiment of the invention, the compounds of the formula | are ~ administered in combination with an MTP inhibitor, such as, for example, Bay 13- 9952, BMS-201038, R-103757.

In one embodiment of the invention, the compounds of the formula | are administered in combination with a bile acid absorption inhibitor , such as, for example, HMR 1453.

In one embodiment of the invention, the compounds of the formula | are administered in combination with a CETP inhibitor, such as, for example, Bay 194789. in one embodiment of the invention, the compounds of the formula | are administered in combination with a polymeric bile acid adsorber, such as, for example, cholestyramine, colesolvam.

In one embodiment of the invention, the compounds of the formula | are administered in combination with an LDL receptor inducer, such as, for example,

HMR1171, HMR1586.

In one embodiment of the invention, the compounds of the formula | are administered in combination with an ACAT inhibitor, such as, for example, avasimibe.

In one embodiment of the invention, the compounds of the formula | are administered in combination with an antioxidant, such as, for example, OPC-14117.

In one embodiment of the invention, the compounds of the formula | are administered in combination with a lipoprotein lipase inhibitor, such as, for example,

NO-1886.

In one embodiment of the invention, the compounds of the formula | are administered in combination with an ATP citrate lyase inhibitor, such as, for ~ example, SB-204990.

In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor, such as, for example, BMS-188494. in one embodiment of the invention, the compounds of the formula | are administered in combination with a lipoprotein(a) antagonist, such as, for example,

CI-1027 or nicotinic acid.

In one embodiment of the invention, the compounds of the formula | are administered in combination with a lipase inhibitor, such as, for example, orlistat.

In one embodiment, of the invention the compounds of the formula | are administered in combination with insulin.

In one embodiment, the compounds of the formula | are administered in combination with a sulphonyl urea, such as, for example, tolbutamide, glibenclamide, glipizide or gliclazide. :

In one embodiment, the compounds of the formula | are administered in combination with a biguanide, such as, for example, metformin.

In yet another embodiment, the compounds of the formula | are administered in combination with a meglitinide, such as, for example, repaglinide.

In one embodiment, the compounds of the formula | are administered in combination with a thiazolidindione, such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone, or the compounds disclosed by Dr. Reddy's Research Foundation in

‘ methoxy]phenyl]methyi]-2,4-thiazolidindione. .

In one embodiment, the compounds of the formula | are administered in combination with an a-glucosidase inhibitor, such as, for example, miglitol or acarbose.

In one embodiment, the compounds of the formula | are administered in combination with an active compound which acts on the ATP-dependent potassium channel of beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, gliazide or repaglinide.

In one embodiment, the compounds of the formula | are administered in combination with more than one of the abovementioned compounds, for example in combination with a sulphonyl urea and metformin, a sulphonyl urea and acarbose, repaglinide and metformin, insulin and a sulphony! urea, insulin and metformin, insulin and troglitazon, insulin and lovastatin, etc.

In a further embodiment, the compounds of the formula | are administered in combination with CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP agonists, urocortin agonists, B3- agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotonin and noradrenergic compounds, SHT agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone-releasing compounds, TRH agonists, decoupling protein 2- or 3 modulators, leptin agonists,

DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR modulators,

RXR modulators or TR-B agonists.

In one embodiment of the invention, the further active compound is leptin.

In one embodiment, the further active compound is dexamphetamine or amphetamine.

In one embodiment, the further active compound is fenfluramine or dexfenfluramine.

In yet another embodiment, the further active compound is sibutramine.

In one embodiment, the further active compound is Orlistat. :

In one embodiment, the further active compound is mazindol or phentermine.

In one embodiment, the compounds of the formula | are administered in combination with fibers, preferably insoluble fibers, such as, for example, Caromax®. The combination with Caromax=® can be given in one preparation or by separate administration of compounds of the formula | and Caromax*. Here, Caromax=® can also be administered in the form of food, such as, for example, in bakery goods or muesli bars. Compared to the individual active compounds, the combination of compounds of the formula | with Caromax= is, in addition to an enhanced action, in particular with respect to the lowering of LDL cholesterol, also characterized by its improved tolerability.

Itis to be understood that each suitable combination of the compounds according to the invention with one or more of the compounds mentioned above and optionally one or more further pharmacologically active substances is included in the scope of the present invention.

The invention furthermore provides both stereocisomer mixtures of the formula | and the pure stereoisomers of the formula |, and diastereomer mixtures of the formula and the pure diastereomers. The mixtures are separated by chromatographic means.

Preference is given to both racemic and enantiomerically pure compounds of the formula | of the following structure:

OH :

R6

DS R2

N

R5 0 Dy"

R4

I

Preference is furthermore given to compounds of the formula | in which the L radicals have the following meaning:

Oo 22°

RT

R10

SN —, x. Rs

R9 (+ Formula J

L

The invention furthermore provides a process for preparing the compounds of the formula I, which comprises obtaining the compounds of the formula | by proceeding analogously to the reaction scheme below.

- 1 - 1

ES ON ¢ SPE

R6 - [ EE i)

N —

R5 o R3 RS o N R3 o, 0

S hy

RS

~

N

L H

R4" is (Co-Cao)-alkylene in which one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)-, -CH=CH-, -C=C-, -N((C4-Cs)-alkyl)- or -NH-.

Alternatively, attachment to the L group is via ring A or ring C.

The examples below serve to illustrate the invention in more detail, without limiting the invention to the products and embodiments described in the examples.

Examplel

O0— 0, ,0

OH @ s ® h -

N

OH

Qo A ®

N

H H

N-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H- benzo[b]thiepin-5-yl)-phenyl}-5-{4-[3-(3-hydroxy-3-phenylpropyl)-2-(4-methoxy- phenyl)-4-oxoazetidin-1-yllbenzylamino}pentanamide (1) 100 mg of N-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetra-

® 15 hydro-1 H-benzo[b]thiepin-5-yl)phenyl]-5-bromopentanamide and 70 mg of 1-(4- j aminomethyliphenyl)-3-(3-hydroxy-3-phenylpropyl)-4-(4-methoxyphenyl)azetidin-2- one are dissolved in 5 ml of dimethylformamide and, with stirring, heated at 80° C for about 2 to 3 hours. After the reaction has ended (monitored by thin-layer chromatogram or HPLC-MS), the solvent is removed under reduced pressure and the residue is purified by chromatography. This gives product 1 of molecular weight 929.24 (CssHesN4O+S); MS (FAB): 929 (M+H).

Example II o, 0 ]

SC

H o N Q

H

JH

4) 8}

F

N-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H- benzo[b]thiepin-5-yl)phenyl]-N’-4-[1-(4-fluorophenyl)-3-(3-hydroxy-3-phenylpropyl)-4- oxoazetidin-2-yilbenzyl-hexanediamide (8) a) 1-(2-Oxo-4-phenyloxazolidin-3-yl)-5-phenylpentane-1,5-dione (2) 10 g of benzoylbutyric acid and 12.5 ml of triethylamine are dissolved in 55 ml of dichloromethane. After 5 min at room temperature, 6.2 mi of pivaloyl chloride are added over a period of 30 min, and the mixture is stirred for 2 hours. 5.9 g of 4-phenyloxazolidin-2-one in 6 ml of dimethylformamide and 0.9 g of 4-(dimethyl- : amino)pyridine are then added. The mixture is heated at reflux for about 7 hours (monitored by TLC). After the reaction has ended, the mixture is put into 15 ml of 2N sulfuric acid and stirred briefly, and the phases are then separated. The org. phase is washed with 5 percent strength bicarbonate solution and, after drying,

® 16 concentrating and recrystallization from ethyl acetate/n-heptane, the product of ) molecular weight 337.4 (C20H1sNO4); MS (DCI+): 338 (M+H"), is obtained. By the same route, optically active/enantiomerically enriched 2 is obtained when optically active/enantiomerically enriched 4-phenyloxazolidin-2-one is used. b) 3-(5-Hydroxy-5-phenyipentanoyl)-4-phenyloxazolidin-2-one (3)

Under argon and at a temperature between 0° and -5°C, 5 g of 1-(2-ox0-4-phenyl- oxazolidin-3-yl)-5-phenylpentane-1,5-dione in 20 ml of dichloromethane are slowly, over a period of about 3 hours, added to a solution of 1.5 ml of boron- dimethylsulfide-complex in 25 ml of dichloromethane. The mixture is stirred at the same temperature for another 2 hours, the reaction being monitored by thin-layer chromatography. After the reaction has ended, 2 ml of methanol and 1.5 ml of 35 percent strength hydrogen peroxide solution and 1.1 mi of 3N sulfuric acid are added at below 0°C, and the mixture is stirred at room temperature for another 15 min. After phase separation, the organic phase is washed successively with 2N sulfuric acid, 5% strength sodium bisulfite solution and 10 percent strength sodium chloride solution and then dried and concentrated. After chromatography (SiO, ethyl acetate/n-heptane = 1:1, the product of molecular weight 339.4 (C2H2:NO,); MS (DCl+): 322 (M+H'-H20); (ESI+): 403 (M+Na*+CH,CN), 362 (M+Na*) is obtained. By adding optically active 1-methyl-3,3-diphenyltetrahydropyrrolo[1,2- c][1,3,2]Joxazaborole (S or R, 0.75 ml) at from 0° to —5°C to the reaction mixture prior to the addition of 1-(2-oxo-4-phenyloxazolidin-3-yl)-5-phenylpentane-1,5-dione, by the same route, 3 is obtained in diastereomerically enriched form. c) 4-[1-(4-Fluorophenylamino)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)-5-phenyl-5- trimethylsilanyloxypentyllbenzonitrile 4) 3.3 g of 3-(5-hydroxy-5-phenylpentanoyl)-4-phenyloxazolidin-2-one and 3.93 g of 4-[(4-fluorophenylimino)methyl]benzonitrile, dissolved in 55 ml of dichloromethane, are cooled to —10°C, and 8.5 mi of diisopropylethylamine are added slowly. Over a period of 30 min, 5.3 ml of chlorotrimethyisilane are then added such that the

® 17 temperature remains below —5°C. After one hour, the mixture is cooled to —30°C, 1.1 ml of titanium tetrachloride are added at below —25°C and the mixture is then stirred at this temperature overnight. After the reaction has ended, 4 mi of glacial acetic acid are added dropwise at —25°C, the mixture is stirred for another 15 min, added, at 0°C, to 50 mi of 7 percent strength tartaric acid and stirred for another hour, and 25 ml of 20 percent strength sodium bisulfite solution are then added and stirring is continued for another 45 min. After phase separation, the organic phase is washed with about 40 ml of water, dried and concentrated to about 15 ml. 2.7 ml of bistrimethyisilylacetamide are then added, and the mixture is heated at reflux for 30 min. After cooling to room temperature, the mixture is concentrated, giving, after crystallization of the residue from ethyl acetate/n-heptane, the product of molecular weight 635.8 (Ca7H3sFN304Si); MS (ESl+): 636 (M+H™). d) 4-[1-(4-Fluorophenyl)-3-(3-hydroxy-3-phenylpropyl)-4-oxo-azetidin-2-yijbenzo- nitrile (5) 2.7 g of 4-[1 -(4-fluorophenylamino)-2-(2-oxo-4-phenyloxazolidine-3-carbonyt)-5- phenyl-5-trimethylsilanyloxypentyllbenzonitrile in 30 ml of tert-butyl methyl ether, 1.6 ml of bistrimethyisilylacetamide and 0.2 g of tetrabutylammonium fluoride trihydrate are heated at reflux for 3 hours. The mixture is allowed to stand overnight, 0.2 ml of glacial acetic acid are added, and the mixture is stirred for 15 min and then substantially concentrated. 15 ml of a mixture of isopropanol/2N sulfuric acid = 10:1 are added, and the mixture is stirred at room temperature for 1 hour. The mixture is then treated with a little solid sodium bicarbonate and again substantially concentrated and the residue is taken up in ethyl acetate and washed with water.

The residue of the dried organic phase is purified by column filtration (SiO,, ethyl acetate/n-heptane = 1:1). This gives the product of molecular weight 400.5 (C25H21FN2O2); MS (DCI+): 401 (M+H™), 383 (M+H"-H,0). e) 4-(4-Aminomethylphenyl)-1-(4-fluorophenyl)-3-(3-hydroxy-3-phenylpropyl)- azetidin-2-one (6)

® 18 930 mg of 4-[1-(4-fluorophenyl)-3-(3-hydroxy-3-phenylpropyl)-4-oxo-azetidin-2-yl}- benzonitrile, dissolved in 100 ml of ethanol, are admixed with 4 ml of conc. ammonia and hydrogenated for 20 hours over Raney Ni, at room temperature and a hydrogen pressure of 20 bar.

The catalyst is filtered off and the filtrate is concentrated under reduced pressure, giving, after chromatography (SiO,, dichloromethane/methanol =

10:1), the product of molecular weight 404.5 (C2sH2sFN2O,); MS (DCl+): 405 (M+HY), 387 (M+H'-H,0). f) 5-[3-(3-Butyl-7-dimethylamino-3-ethyl-4-hydroxy-1 ,1-dioxo-2,3,4,5-tetrahydro-1H-

benzo[b]thiepin-5-yl)-phenylcarbamoyl]pentanoic acid (7)

2 g of 5-(3-aminophenyl)-3-butyl-7-dimethylamino-3-ethyl-1,1-dioxo-2,3,4,5-tetra- hydro-1H-benzo[b]thiepin-4-ol, 3.4 g of hexanedioic acid, 1.04 g of dicyclohexyl- carbodiimide and 640 mg of benzotriazol-1-ol in 80 ml of tetrahydrofuran are stirred at room temperature overnight.

The mixture is concentrated, the residue is taken up in ethyl acetate, excess urea is removed by filtration and the mixture is washed with water.

The residue of the dried organic phase is purified by column filtration (SiO, dichloromethane/methanol = 20:1). This gives the product of molecular weight 558.7 (C30H42N206S); MS (ESI+): 559 (M+HY).

g) N-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-

benzofb]thiepin-5-yl)phenyl]-N'-4-[1-(4-fluorophenyl)-3-(3-hydroxy-3-phenyl- propyl)-4-oxoazetidin-2-yl]benzyl-hexanediamide (8)

83 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-(3-hydroxy-3-phenyipropyl)- azetidin-2-one, 115 mg of 5-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1 , 1-dioxo- 2,3,4,5-tetrahydro-1H-benzo[b]thiepin-5-yl)phenylcarbamoyljpentanoic acid, 45 mg of dicyclohexylicarbodiimide and 35 mg of benzotriazol-1-ol in 5 ml of tetrahydrofuran are stirred at room temperature overnight.

The mixture is concentrated under reduced pressure giving, after chromatography (SiO,, dichioromethane/methanol = 20:1), the product of melting point 150°C and molecular weight 945.2 (CssHesFN4O7S); MS (ESI+): 945 (M+H™).

Example lI ~ 0,0

S

H

N OH

OH 4 RY

Y N

® :

N

F

"TQ

F

N-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H- benzofb]thiepin-5-yl)phenyl]-N'-4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl]-4-oxo-azetidin-2-yl}benzyl-hexanediamide (12) a) 4-[5-(4-Fluorophenyl)-1-(4-fluorophenylamino)-2-(2-oxo-4-phenyloxazolidine-3- carbonyl)-5-trimethylsilanyloxypentyl]benzonitrile (9)

Preparation analogous to example Il using 3-{5-(4-fluorophenyl)-5-hydroxy- pentanoyl]-4-phenyloxazolidin-2-one

The product of molecular weight 653.8 (Ca7Hs7F2N304Si); MS (ESI+): 654 (M+H").

Db) 4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl}-4-oxo-azetidin-2-yl}- benzonitrile (10)

Preparation analogous to example Il, using 4-[5-(4-fluorophenyl)-1-(4-fluorophenyl- amino)-2-(2-oxo-4-phenyloxazolidin-3-carbonyl)-5-trimethyisilanyloxypentyi]benzo- nitrile; product of molecular weight 418.5 (C2sH20F2Nz0z); MS (ESI+): 419 (M+H").

Cc) 4-(4-Aminomethyiphenyl)-1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-

propyl]-azetidin-2-one (11)

Preparation analogous to example II; using 4-{1-(4-fluorophenyl)-3-[3-(4-fluoro- phenyl)-3-hydroxypropyl]-4-oxo-azetidin-2-yl}benzonitrile; product of molecular weight 422.5 (C2sH24F2N205); MS (ESI+): 423 (M+H"). d) N-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1, 1 -dioxo-2,3,4,5-tetrahydro-1H- benzo[b]thiepin-5-yl)phenyl]-N'-4-{1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl]-4-oxoazetidin-2-yl}benzyl-hexanediamide (12)

Preparation analogous to example II; product of molecular weight 963.2 (CssHeaF2N4O7S); MS (ESI+): 963 (M+H").

Example V

O0— ® 0..,0

N AWA

0 0 Ss

ON ® h / o N CI

H

N- [3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H- benzo[b]thiepin-5-yl)phenyl]-N’-4-[3-(3-hydroxy-3-phenylpropyl)-2-(4-methoxy- phenyl)-4-oxo-azetidin-1-yllbenzyl-hexanediamide (15)

Preparation analogous to example lll, starting from 1-(4-aminomethylphenyl)-3-(3- hydroxy-3-phenylpropyl)-4-(4-methoxyphenyl)azetidin-2- one; product of molecular weight 957.2 (CseHssN4OsS); MS (ESI+): 957 (M+H*).

Example Vi ~ o..0

Vs?

SN ®

N / OH r { o

FE en AO

C oo

H

N

ERD) : F [2-(2-{[3-(3-Butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro- 1H-benzo[b}thiepin-5-yl)-phenylcarbamoyl]methoxy}ethoxy)ethoxy]-[N-{4-[1-(4-fluoro- phenyl)-3-(3-hydroxy-3-phenylpropyl)-4-oxoazetidin-2-yl]benzyl}jacetamide (16)

Preparation analogous to example Il, starting from 83 mg of 4-(4-aminomethyl- phenyl)-1-(4-fluorophenyl)-3-(3-hydroxy-3-phenylpropyl)azetidin-2-one and 130 mg of [2-(2-{[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro- 1H-benzo[b]thiepin-5-yl)phenylcarbamoyl]methoxy}ethoxy)ethoxylacetic acid; chromatography: SiO», dichloromethane/methanol = 20:1 ; product of melting point 120°C and molecular weight 1021.3 (Cs7Hg7FN4O10S); MS (ESI+): 1021 (M+H").

Example Vii

NZ no / 0

CC ©oe

F N

0 eon

F F

F

(3-Butyl-3-ethyl-5-[3-(2-{2-{(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-

® 22 propyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)methoxylethoxy}acetylamino)phenyi]-4-

R hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1 H-benzolb]thiepin-7-yl)dimethylammonium; trifluoroacetate (18) a) (2-{[3-(3-Butyl-7-dimethylamino-3-ethyl-4-hydroxy-1, 1 -dioxo-2,3,4,5-tetrahydro- 1H-benzo[b]thiepin-5-yi)-phenylcarbamoyllmethoxy}ethoxy)acetic acid 17

Over a period of 2 h, 500 mg of 5-(3-aminophenyl)-3-butyl-7-dimethylamino-3-ethyi- 1,1-dioxo-2,3,4,5-tetrahydro-1H-1-benzo[b]thiepin-4-ol in 8 ml of THF are added dropwise to a solution of 965 mg of 10 g of dioxooctanedioic acid, 188 mg of hydroxybenzotriazole and 287 mg of dicyclohexylcarbodiimide in 10 ml of tetrahydrofuran (THF). The mixture is stirred at room temperature for 12 h. The reaction solution is concentrated, taken up in 2 N hydrochloric acid and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate, concentrated and purified by HPLC (Merck-Hibar-Lichrospher 100-RP-18, water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) = 80/20 -> 10/90). This gives 17.

Ca0Ha1N20sS+ (590.74) MS (ESI) 592 (M + H) ocd : = a o | ron

F F

F b) (3-Butyl-3-ethyl-5-[3-(2-{2-[(4-{1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl}-4-oxo-azetidin-2-yl}-benzylcarbamoyl)methoxy]ethoxy}acetylamino)phenyl}-4- hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1 H-benzo[bj]thiepin-7-yl)dimethylammonium; trifluoroacetate (18)

B A solution of 100 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluoro- phenyl)-3-hydroxypropyljazetidin-2-one, 209 mg of (2-{[3-(3-butyl-7-dimethylamino-3- ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-benzo[bjthiepin-5-yl)-phenyl- carbamoyllmethoxy}ethoxy)acetic acid, 93 ul of diisopropylcarbodiimide and 65 mg of hydroxybenzotriazole in 2 ml of methylene chloride is stirred at room temperature for 12 h. Water is added, and the mixture is extracted with methylene chloride. The organic phase is dried over magnesium sulfate and concentrated, and the residue is separated by HPLC (Knauer Eurospher-100-10-C18, water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) = 80/20 -> 10/90). This gives 18.

Cs7HsaFsN4O11S1 (1109.23) MS (ESI) 977 (M + H — H,0)

Examples (VIII-XXIV) below are prepared analogously to example VII:

Example Vii 0 0s’ >N J OH ; AQ

SNPS SE

NN

Te N

F N F [o) o F

Q, 7

F

(3-Butyl-3-ethyl-5-[3-(2-{2-[(3-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl}-4-oxoazetidin-2-yl}benzylcarbamoyl)methoxy]ethoxy}acetylamino)phenyi}-4- hydroxy-1,1-dioxo-2,3,4,5-tetrahydro- 1H-benzo[b]thiepin-7-yl)dimethylammonium trifluoroacetate (19)

Cs7HesFsN4011S4 (1109.23) MS (ESI) 977 (M + H — H20)

Example IX

. 0=g2 “Nn J OH / ¢ QO

NF nh ® fr o H

F N F< o [®] fg OH

F

3-Butyl-3-ethyl-5-{3-[2-(2-{2-[(4-(1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)methoxy]ethoxy}ethoxy)acetylamino]- phenyl}-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yl)dimethyl- ammonium trifluoroacetate (21) ,0

O=g~

Jo

OH

CJ

H

0] N

Aol No

A a) [2-(2-{[3-(3-Butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro- 1H-benzof[b]thiepin-5-yl)-phenylcarbamoyl]methoxy}ethoxy)ethoxylacetic acid (20)

Ca2HaeN203S, (634.3) MS (ESI) 635 (M + H) 0=g"> oN _ OH r ; 1,0

Ion ed YT °F 0

F N F—4

Tq .

b) (3-Butyl-3-ethyl-5-{3-[2-(2-{2-[(4-{1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3- ) hydroxypropyi]-4-oxoazetidin-2-yl}benzyicarbamoyl)methoxy]ethoxy}ethoxy)acetyl- amino]phenyl}-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yl)- dimethylammonium trifluoroacetate (21)

CsoHegFsN4012S4 (1 153.28) MS (ESI) 1039 M + H)

Example X 0s

WSJ

N OH

: PQ

OH

() No S—0 oA ® .

N

F

ARO TENA

F

(3-Butyl-3-ethyl-5-{3-[2-(2-{2-[(3-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)methoxylethoxy}ethoxy)acetylamino]- phenyl}-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yl)-dimethyl- ammonium trifluoroacetate (22)

CsoHgoFsN4012S, (1 153.28) MS (ESI) 1040 (M + H)

Example XI 0=g°

WL

" ; < @ SPO § ® °

F N

0 F [o)

Qo AL,

(3-Butyl-3-ethyl-5-{3-[11-(4-{1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl]-4-oxoazetid in-2-yl}benzylcarbamoyl)undecanoylamino]phenyl}-4-hydroxy-1 ,1- dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yl)dimethylammonium trifluoroacetate (24) 0xg?>

Lh

OH i OJ

N

EE

8 o a) 11-[3-(3-Butyl-7-dimethylamino-3-ethyl-4-hydroxy- 1 ,1-dioxo-2,3,4,5-tetrahydro-1H- benzo[b]thiepin-5-yl)phenylcarbamoyljundecanoic acid (23)

CasHs4N206S, (642.91) MS (ESI) 643 M + H) 0=g"2 “SN J) OH /

[0]

OH a ES SEN

N

(J °

F N o F 0

F

Qo, 44,

F b) (3-Butyl-3-ethyl-5-{3-[11-(4-{1 -(4-fluorophenyi)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)undecanoylamino]phenyl}-4-hyd roxy-1,1- dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yl)dimethylammonium trifluoroacetate (29)

CesH77FsN4OgS1 (1161.39) MS (ESI) 1047 (M + H)

Example XII : 0 0=g” -

New)

N OH s , 0

OH H

Ja aa ~~

H

® :

N

F 0 0 FE 0

F

, on

F

(3-Butyl-3-ethyl-5-{3-[11-(3-{1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl]-4-oxoazetidin-2-yl}benzyicarbamoyl)undecanoylamino]phenyl}-4-hyd roxy-1,1- dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yl)dimethylammonium trifluoro- acetate (25)

CeaH77FsN4OsS4 (1161.39) MS (ESI) 1047 (M + H)

Example XXI

OH o0— fo) =s

F F \

N —N 0)

QI J oO

N ~~ \A0 N 8)

H H

(3-Butyl-3-ethyl-5-{3-[2-(2-{2-[(4-[3-(3-hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)- 4-oxoazetidin-1-ylbenzylcarbamoyl)methoxy]ethoxy}ethoxy)acetylamino]phenyi}-4- hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yl)dimethylammonium trifluoroacetate (38)

CeoH73F3N4013S; (1 147.33) MS (ESI) 1033 M + H)

Example XXII ’ (o] os - vl / ge 0 H " () Lonesome ® 0 fo

F N

0 1D] F< on

F

{3-Butyl-3-ethyl-5-[3-(3-{2-{2-(2-{2-[2-(3-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3- hydroxypropyl}-4-oxoazetidin-2-yl}benzylcarbamoyl)ethoxy]ethoxy}ethoxy)ethoxy]- 5S ethoxy}propionylamino)phenyl]-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro- 1 H-benzo[b]- thiepin-7-yl}dimethylammonium trifluoroacetate (42) 0 > oO Oo (0 0

Ao NNN IN NN ~N(

J (0) a) tert-Butyl 3-[2-(2-{2-[2-(2-tert-butoxycarbonylethoxy)ethoxy]ethoxy}ethoxy)- ethoxy]propionate (39) 0.4 g of sodium is added to a solution of 91 g of tetraethylene glycol in 250 mi of tetrahydrofuran, and the mixture is stirred at room temperature. Once the sodium has dissolved, 145 mi of tert-butyl acrylate are added. The mixture is stirred for 12 h.

The reaction solution is neutralized with ammonium chloride, concentrated, taken up in aqueous sodium chloride solution and extracted with ethyl acetate. The organic phase is concentrated. The residue is 39.

C22H4209 (450.57) MS (ESI) 339 (M + 3*H — 2* tert-Bu)

Db) 3-[2-(2-{2-[2-(2-Carboxyethoxy)ethoxylethoxy}ethoxy)ethoxy]propionic acid (40)

A solution of tert-butyl 3-[2-(2-{2-[2-(2-tert-butoxycarbonylethoxy)ethoxy]ethoxy}- ) ethoxy)ethoxy]propionate 24 in 50 ml of methylene chloride and 50 mi of trifluoro- acetic acid is stirred for 2 h and then concentrated. The residue is taken up in 1N hydrochloric acid and extracted with methylene chloride. The organic phase is concentrated and contains 40.

C14H260, (338.36) MS (ESI) 339 (M + H) ,0

Ao

OH

0

OO Te Oe ON 0) 0) c) 3-(2-{2-[2-(2-{2-[3-(3-Butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5- tetrahydro-1H-benzo[b}thiepin-5-yl)phenyicarbamoyljethoxy}ethoxy)ethoxylethoxy}- ethoxy)propionic acid (41)

The synthesis is carried out analogously to 17.

CaoHeoN2011S, (750.97) MS (ESI) 751 (M + H) [o] os’

WJ

MN OH

OH N 0 (o) ~o—L 4g

NN No NNN N ® : . 0

N

F F

“Q 7

F d) {3-Butyl-3-ethyl-5-[3-(3-{2-[2-(2-{2-[2-(3-{1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)- 3-hydroxy-propyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)ethoxylethoxy}ethoxy)- iB ethoxylethoxy}propionylamino)phenyl]-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H- benzo[b]thiepin-7-yl}dimethylammonium trifluoroacetate (42)

CesHg1FsNs014S1 (1269.44) MS (ESI) 1155 (M + H)

Example XXII

TR

Nr Omg Og Oman Sg @® le} F [o]

Q Te

F

[3-Butyl-3-ethyl-5-(3-{3-[2-(2-{2-{2-(2-{2-[2-{3-[1 ~(4-fluorophenyl)-3-[3-(4-fluorophenyl)- 3-hydroxypropyl]-4-oxo-azetidin-2-yllbenzylcarbamoyl}ethoxylethoxy}ethoxy)ethoxy]- ethoxy}ethoxy)ethoxy]propionylamino}phenyl)-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro- 1H-benzo[b]thiepin-7-ylJdimethylammonium trifluoroacetate (46) a) tert-Butyl 3-(2-{2-[2-(2-{2-[2-(2-tert-butoxycarbonylethoxy)ethoxy] ethoxy}ethoxy)- ethoxy]ethoxy}ethoxy)propionate (43)

The synthesis is carried out analogously to 39.

C26Hs0041 (538.68) MS (ESI) 427 (M + 3*H — 2* tert-Bu)

b) 3-(2-{2-[2-(2-{2-{2-(2-Carboxyethoxy)ethoxylethoxy}ethoxy)ethoxy]ethoxy}- ) ethoxy)propionic acid (44) ~

The synthesis is carried out analogously to 40.

C18H34011 (426.47) MS (ESI) 427 (M + H) 0s? eahe

OH

H

HO ON NO 0 Ve Va SN N CJ o (e] o

TY ~Y c) 3-{2-[2-(2-{2-[2-(2-{2-[3-(3-Butyl-7-dimethylamino-3-ethyl-4-hydroxy-1 ,1-dioxo- 2,3,4,5-tetrahydro-1H-benzo[b]thiepin-5-yl)phe nylcarbamoyl]ethoxy}ethoxy)ethoxy]- ethoxy}ethoxy)ethoxylethoxy}propionic acid (45)

The synthesis is carried out analogously to 17.

Ca3HssN203S, (839.09) MS (ESI) 840 (M + H)

[0] 0=g”

Sl

Nl NN SN NY J 0 F [o] ® 5 0 on

F d) [3-Butyl-3-ethyl-5-(3-{3-[2-(2-{2-[2-(2-{2-[2-{3-[1 -(4-fluorophenyl)-3-[3-(4-fluoro- phenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]benzylcarbamoyl}ethoxylethoxy}- ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]propionylamino}phenyl)-4-hydroxy-1 ,1-dioxo- 2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yljdimethylammonium trifluoroacetate (46)

CeoHaoFsN4O16S1 (1357.55) MS (ESI) 1243 (M + H)

’ Example XXIV RN oss? re [o} pene ° F 0

N he CA

F

[3-Butyl-3-ethyl-5-(3-{3-[2-(2-{2-[2-({2-{2-[2-(4-{ 1-(4-fluorophenyl)-3-[3-(4-fluoro- phenyl)-3-hydroxypropyl}-4-oxoazetidin-2-yl}benzylcarbamoyi}ethoxy)ethoxy}- ethoxy}ethoxy)ethoxy]propionylamino}phenyl)-4-hydroxy-1, 1-dioxo-2,3,4,5- tetrahydro-1H-benzo[b]thiepin-7-ylJdimethylammonium trifluoroacetate (47)

CesHas FsN4O14S4 (1269.44) MS (ESI) 1243 M + H)

Example XXV 0s? she

OH

CJ

N

NNN

OH [1 H [o]

Jn 0

RC vo

F F IF

(3-Butyl-3-ethyl-5-{3-[8-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hyd roxy-propyl}- 4-oxoazetidin-2-yl}benzylamino)octanoylamino]phenyl}-4-hydroxy-1,1-dioxo-2,3,4,5- tetrahydro-1H-benzo[b]thiepin-7-yl)dimethylammonium trifluoroacetate (50) a) 7-[3-(3-Butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H- benzo[b]thiepin-5-yl)-phenylcarbamoyl}heptanoic acid (48)

) The synthesis is carried out analogously to 17. ~

Ca3HsN206S; (600.82) MS (ESI) 601 M + H) ,0 . O=g” ak

OH i 9

H

RV PVN.

N i. 5 b) N-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1 , 1-dioxo-2,3,4,5-tetrahydro-1H- benzo[b]thiepin-5-yl)phenyl}-N'-methoxymethyl-octanediamide (49)

At room temperature, a solution of 223 mg of O,N-dimethyl-hydroxylamine hydrochioride and 391 ul of diisopropylethylamine in 5 ml of acetonitrile is added to a solution of 550 mg of 7-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1, 1-dioxo- 2,3,4,5-tetrahydro-1-benzo[b]thiepin-5-yl)phenylcarbamoyl]heptanoic acid, 311 ul of diisopropylcarbodiimide and 272 mg of hydroxybenzotriazole in 10 ml of methylene chloride, and the mixture is stirred for 12 h. The reaction solution is concentrated and purified by HPLC (Merck-Hibar-Lichrospher 100-RP-18, water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) = 80/20 -> 10/90).

CasHs3N306S1 (643.89) MS (ESI) 644 (M + H)

® 34 . os?

AJ :

OH

CJ

NNN

OH [> 0 : 0 TL on

F F JF c) (3-Butyl-3-ethyl-5-{3-[8-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl]-4-oxoazetidin-2-yl}benzylamino)octanoylamino]phenyl}-4-hydroxy-1,1-dioxo- 2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yl)dimethylammonium trifluoroacetate (50)

At -78°C, 0.22 ml of a 1M solution of diisobutylaluminum hydride in hexane is added to a solution of 160 mg of N-[3-(3-butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1- dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepin-5-yl)phenyi]-N’-methoxymethyl-octane- diamide 34 in 1 ml of tetrahydrofuran, and the mixture is stirred for 30 min. Water is added to the reaction solution, and the mixture is extracted with methylene chloride.

The extract is concentrated and the residue is taken up in 3 ml of a mixture of tetrahydrofuran and methanol (1/1, 1% acetic acid). 131 mg of 4-(3-aminomethyl- phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one and 58 mg of sodium cyanoborohydride are added. After 12 h, water is added to the mixture, the mixture is extracted with methylene chloride and the organic phase is concentrated. The residue is purified by HPLC (Knauer Eurospher-100-10-C18, water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) = 80/20 -> 10/90). CsgH72F2N4O6S; (991.30) MS (ESI) 991 (M + H)

Example XXVI . 0x” i we

OH

ANON N @,

FY

OH ® 0

Os 9 ae 4

F

F {OF {3-Butyl-3-ethyl-5-[3-(2-{2-{2-(3-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy- propyl]-4-oxoazetidin-2-yl}benzylamino)ethoxylethoxy}acetylamino)phenyl}-4- hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepin-7-yl}dimethylammonium trifluoroacetate (52) a) 2-(2-{[3-(3-Butyl-7-dimethylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro- 1H-benzo[b]thiepin-5-yl)phenylcarbamoyl]methoxy}ethoxy)-N-methoxy-N-methyl- acetamide (51)

Synthesis analogously to 49, starting from 17.

Ca2Ha7N308S, (633.81) MS (ESI) 634 M + H) 0s?

LO

OH on MD

NOON

TY

SS

OSs

RC A

F FI>F

F

Claims

® 02/50068 48 PCT/EP01/14532 : Claims:

1. A compound of the formula |, R1 w 7 {0 el R5 oO el R4 in which R1, R2, R3, R4, R5, R6 independently of one another are (Co-Cso)- alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)-, -CH=CH-, -C=C-, -N((C1-Cs)-alkyl)- or -NH-; H, F, Cl, Br, I, CF3, NOz, CN, COOH, COO(C1-Ce)alkyl, CONH,, CONH(C+-Ce)alkyl, CON[(C4-Cg)alkyl], (C1-Ce)-alkyl, (C2-Ce)-alkenyl, (C2-Ce)-alkynyl, O-(C4-Ce)-alkyl, where one or more hydrogens in the alkylene radicals may be replaced by fluorine; SO2-NH2, SO.NH(C1-Ce)-alkyl, SO2N[(C+-C¢)-alkyl]z , S-(C4-Cs)-alkyl, S- (CH2)a-phenyl, SO-(C+-Ce)-alkyl, SO-(CH,)q-phenyl, SO,-(C1-Ceg)-alkyl, SO2-(CHz)s-phenyl, where n = 0 — 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CFs, NO, CN, OCF, O-(C4-Ce)-alkyl, (C1-Cé)-alkyl, NHa; NHz, NH-(C1-Ce)-alkyl, N((C+-Ce)-alkyl)z, NH(C1-C7)-acy!, phenyl, O-(CHz)n-phenyl, where n = 0 — 6, where the phenyl ring may be mono-

to trisubstituted by F, Cl, Br, I, OH, CF3, NO, CN, OCF3, O-(C4-Ce)- : alkyl, (C+-Ce)-alkyl, NHz, NH(C;-Cg)-alkyl, N((C1-Ce)-alkyl),, S02-CH;, COOH, COO-(C1-Ce)-alkyl, CONH,; L Oo Sg , oO R7 R10~_ 9g ° N Re N (S Formula L R7 is methyl, ethyl, propyl, butyl; R8 is H, OH, NHz, NH-(C4-C¢)-alkyl; R9 is methyl, ethyl, propyl, butyl; R10 is methyl, ethyl, propyl, butyl; where in each case at least one of the radicals R1 to R6 must have the meaning (Co-Cap)-alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)-, -CH=CH-, -C=C-, -N((C+-C¢)-alkyl)- or -NH-, and its pharmaceutically acceptable salts.

2. A compound of the formula |, as claimed in claim 1, wherein R1, R2, R3, R4, R5, R6 independently of one another are (Co-Cao)- alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)- or -NH-; H, F, Cl, Br, I, CF3, NO2, CN, COOH, COO(C:-Ce)alkyl, CONH, CONH(C+-Ce)alkyl, CON[(C+-Cs)alkyl]z, (C+-Cé)-alkyl, (C2-C¢)-alkenyl, (C2-Ce)-alkynyl, O-(C,-Ce)-alkyl, where one or more hydrogens in the alkylene radicals may be replaced by fluorine; S02-NHz, SONH(C+-Ce)-alkyl, SO2N[(C+-C¢)-alkyl]. , S-(C4-Ce)-alkyl, S- (CHgz)a-phenyl, SO-(C4-Ce)-alkyl, SO-(CHa)n-phenyl, SO»-(C;-Ce)-alkyl, SO2-(CHz)n-phenyl, where n = 0 — 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CFs, NO,, CN, OCF, 0O-(C+-Cé)-alkyl, (C+-Ce)-alkyl, NH; NHz, NH-(C4-Ce)-alkyl, N((C1-Ce)-alkyl)2, NH(C4-C;)-acyl, phenyl, O-(CHz)n-phenyl, where n = 0 — 6, where the phenyl ring may be mono- to trisubstituted by F, Cl, Br, |, OH, CF3, NO,, CN, OCF3, O-(C,-Cs)- alkyl, (C1-Ce)-alkyl, NHz, NH(C4-Cg)-alkyl, N((C1-C¢)-alkyl)z, SO2-CHa, COOH, COO0-(C,-Cg)-alkyl, CONH; 0 , Oo R7 wo Ie N R8 Formula L L

R7 is methyl, ethyl, propyl, butyl; R8 is H, OH, NH, NH-(C1-Ce)-alkyl;

® 51 - R9 is methyl, ethyl, propyl, butyl; R10 is methyl, ethyl, propyl, butyl; where in each case at least one of the radicals R1 to R6 must have the meaning (Co-Cao)-alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)- or -NH-, and its pharmaceutically acceptable salts.

3. A compound of the formula |, as claimed in claim 1 or 2, wherein R1, R2, R3, R4, R5, R6 independently of one another are (Co-Cag)- alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)- or -NH-; H, F, Cl, Br, I, CF3, NO2, CN, COOH, COO(C-Cs)alkyl, CONH,, CONH(C1-Cg)alkyl, CON[(C1-Ce)alkyl]2, (C1-Ce)-alkyl, (C2-Cs)-alkenyl, (C2-Ce)-alkynyl, O-(C4-Ce)-alkyl, where one or more hydrogens in the alkylene radicals may be replaced by fluorine; SO2-NHz, SO.NH(C+-C¢)-alkyl, SO.N[(C1-Cé)-alkyl]> , S-(C1-Cs)-alkyl, S- (CHgz)n-phenyl, SO-(C1-Ce)-alkyl, SO-(CH.)n-phenyl, SO2-(C1-Cg)-alkyl, SOz-(CHz)a-phenyl, where n = 0 — 6 and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF3, NO», CN, OCF, O-(C+-Ce)-alkyl, (C1-Cg)-alkyl, NH; NHz, NH-(C1-Ceg)-alkyl, N((C;-Ce)-alkyl)2, NH(C1-C7)-acyl, phenyl, O-(CHz)n-phenyl, where n = 0 — 6, where the phenyl ring may be mono- to trisubstituted by F, Cl, Br, I, OH, CFs, NO, CN, OCF3, O-(C;-Cq)- alkyl, (C4-Ce)-alkyl, NH, NH(C-Ce)-alkyl, N((C1-Ce)-alkyl)z, SO,-CHs, COOH, COO-(C4-Cg)-alkyl, CONH,; L

0) , oO ao JEL ~~ R8 ; (3 Formula L R7 is methyl, ethyl, propyl, butyl; RSs is H, OH, NHz, NH-(C4-C¢)-alkyl; R9 is methyl, ethyl, propyl, butyl; R10 is methyl, ethyl, propyl, butyl; where one of the radicals R1 or R3 must have the meaning (Co-Cao)-alkylene-L, where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=0)- or -NH-, and its pharmaceutically acceptable salts.

4. - A compound of the formula | as claimed in one or more of claims 1 to 3, wherein R1, R2, R3, R4, R5, R6 independently of one another are -(CH2)o-1-NH- (C=0)0-1-(C3-C2s)-alkylene-(C=0)o.1-NH-L, where one or more carbon atoms of the alkylene radical may be replaced by oxygen atoms; H, F, Cl, Br, I, CF3, NO2, CN, COOH, COO(C;-Cg)alkyl, CONH,, CONH(C1-Ce)alkyl, CON[(C-Cg)alkyl]z, (C1-Ce)-alkyl, (C2-Ce)-alkenyl,

(C2-Ce)-alkynyl, O-(C4-Ce)-alkyl, where one or more hydrogens in the alkylene radicals may be replaced by fluorine; _ SO2-NHz, SO2NH(C1-Ce)-alkyl, SO2N[(C-Ce)-alkyl]z , S-(C1-Ce)-alkyl, S- (CHz)n-phenyi, SO-(C1-Ce)-alkyl, SO-(CH.)a-phenyl, SO,-(C1-Ce)-alkyl, SO2-(CHz)s-phenyl, where n = 0 — 6 and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF3, NO», CN, OCF, O-(C1-Ce)-alkyl, (C1-Ce)-alkyl, NH; NHz, NH-(C+-Ce)-alkyl, N((C1-Ce)-alkyl)>, NH(C+-C;)-acyl, phenyl, O-(CHg)n-phenyl, where n = 0 — 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, NO,, CN, OCF3, O-(C+-Cg)- alkyl, (C1-Ce)-alkyl, NHz, NH(C-Cs)-alkyl, N((C1-Cé)-alkyl)2, SO2-CHj, COOH, COO0O-(C4-Ce)-alkyl, CONH_; L 0) Oo R7 R10~_ 9g y N R8 "© Formula L

R7 is methyl, ethyl, propyl, butyl; R8 is H, OH, NH, NH-(C+-C¢)-alkyl;

Ro is methyl, ethyl, propyl, butyl; R10 is methyl, ethyl, propyl, butyi;

} ® 54 - where one of the radicals R1 to R3 has the meaning -(CHz)o.1-NH-(C=0)o.1-(Cs-Cas)- alkylene-(C=0)o.1-NH-L, where one or more carbon atoms of the alkylene radical may be replaced by oxygen atoms, and its pharmaceutically acceptable salts.

5. A medicament comprising one or more of the compounds as claimed in one or more of claims 1 to 4.

6. A medicament comprising one or more compounds as claimed in one or more of claims 1 to 4 and at least one further active compound.

7. The medicament as claimed in claim 6, comprising, as further active compound, one or more compounds which normalize lipid metabolism.

8. The medicament as claimed in claim 6 or 7, which comprises, as further active compound, one or more antidiabetics, hypoglycemically active compounds, HMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbers, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP citrate lyases inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulphonyl ureas, biguanides, meglitinides, thiolidindiones, : a-glucosidase inhibitors, active compounds which act on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP agonists, urocortin agonists, B3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin-reuptake inhibitors, mixed serotonin and noradrenergic compounds, SHT agonists, bombesin agonists, galanin agonists, growth hormones, growth hormone-releasing compounds, TRH agonists, decoupling protein 2- or 3- modulators, leptin agonists, DA agonists (bromocriptine, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-B-agonists or amphetamines.

9. A compound as claimed in one or more of claims 1 to 4 for use as a medicament for the treatment of impaired lipid metabolism.

10. A process for preparing a medicament comprising one or more of the compounds as claimed in one or more of claims 1 to 4, which comprises mixing the active compound with a pharmaceutically acceptable carrier and bringing this : mixture into a form suitable for administration.

11. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for treating hyperlipidemia.

12. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for lowering the serum cholesterol concentration.

13. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for treating arteriosclerotic symptoms.

14. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for treating insulin resistance.